A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Status:
Not yet recruiting
Trial end date:
2024-10-03
Target enrollment:
Participant gender:
Summary
The aim of the study is to compare the efficacy and safety of two XW003 doses versus
dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus
(T2DM)